RASSF1 and central nervous system cancer: RASSF1 promoter hypermethylation is also reported in osteosarcoma, breast cancer, upper aerodigestive tract cancer, glioma, clear cell carcinoma of the kidney, urothelial carcinoma, thyroid carcinoma, and neuroblastoma [34].